Bausch + Lomb (BLCO) is back in focus after announcing the U.S. launch of Blink Triple Care Preservative Free eye drops, a preservative free, multi dose dry eye product built on a clinically tested formula.

The product launch lands at a time when Bausch + Lomb’s 1 year total shareholder return of 29.05% contrasts with a share price that is down 9.70% over 90 days and 6.76% year to date, suggesting recent momentum has cooled after a stronger year.

If this dry eye update has you thinking more broadly about eye care and medical technology opportunities, it could be worth checking a wider set of healthcare and AI focused companies through the 38 healthcare AI stocks

With BLCO trading at US$15.46, carrying a value score of 5 and an indicated intrinsic discount of about 55%, the real question is whether this gap signals a potential opportunity or whether the market already reflects future growth.

Most Popular Narrative: 60.6% Undervalued

According to a widely followed narrative on Bausch + Lomb, a fair value of $39.23 is set against a last close of $15.46, which implies a sizeable gap that many investors are watching closely.

For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry standard, and not aligned with the obligations of a publicly traded company.

The valuation is based on a detailed cash flow build, a firm discount rate, and assumptions for future margins that place earnings in a very different zone from today. Want to see which revenue path and profitability profile sit behind that $39.23 figure, and how those inputs line up with your own expectations?

Result: Fair Value of $39.23 (UNDERVALUED)

However, that 60.6% discount hinges on assumptions that could be challenged by ongoing governance concerns around AGM disclosure and the current net loss of US$219.0 million.

Next Steps

If this mix of valuation optimism and governance concern feels divided, take a closer look at the underlying data now and shape your own view with the 3 key rewards

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock. Use the Simply Wall Street Screener to uncover other opportunities that fit your style.

• Spot potential growth stories early with 24 elite penny stocks with strong financials and see which smaller companies already pair higher risk with stronger fundamentals.
• Target value focused opportunities by scanning 48 high quality undervalued stocks, which combines quality metrics with pricing that may still leave room on the table.
• Prioritise resilience and sleep a little easier at night by reviewing 63 resilient stocks with low risk scores, which scores well on financial stability and downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.